- ctDNA analysis of SAF-189s efficacy in ALK plus advanced nonsmall cell lung cancer (NSCLC)Yang, J-J.; Zhou, J.; Cheng, Y.; Li, M.; Zhao, Q.; Zhang, Z-Y.; Zang, A.; Fan, Y.; Zhou, Y.; Guo, J.; Zheng, Y.; Wu, Z.; Sun, J.; Xiang, X.; Wang, X.; Wu, Y-L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancerYang, J.; Zhou, J.; Li, M.; Zhang, Z-Y.; Cheng, Y.; Chu, D. H.; Pan, H.; Wang, B.; Chen, G.; Wang, K.; Jiang, L.; Hu, Y.; Shi, J.; Hui, A-M.; Zhou, Y.; Wu, Z.; Sun, J.; Tan, Y.; Xiang, X.; Wu, Y-L.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
- ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)Solomon, B. J.; Ahn, J. S.; Dziadziuszko, R.; Barlesi, F.; Nishio, M.; Lee, D. H.; Lee, J. S.; Zhong, W. Z.; Horinouchi, H.; Mao, W.; Hochmair, M. J.; De Marinis, F.; Migliorino, M. R.; Bondarenko, I.; Lohmann, T. O.; Xu, T.; Gavaldon, A. Cardona; Bordogna, W.; Ruf, T.; Wu, Y. L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.被引 3
会议论文
SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): Results from the dose-finding portion in a single-arm, first-in-human phase I/II study.
3被引16阅读
